59 patents
Utility
Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
19 Jan 23
The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.
Jan ENDELL, Günter FINGERLE-ROWSON, Mark Ping CHAO
Filed: 22 Jun 21
Utility
Antibodies targeting Glycoprotein VI
3 Jan 23
The present disclosure provides antibodies or antibody fragments specific for GPVI.
Kerstin Uhland, Julia Neugebauer, Steffen Runz
Filed: 15 May 19
Utility
Eluate Collection During Antibody Chromatography
29 Dec 22
The present invention relates to an improved method for peak fractionation and eluate collection during chromatography for purification of a human therapeutic antibody.
Daniela DAUBERT, Dominik GELTINGER, Karin FELDERER
Filed: 20 Nov 20
Utility
Method to Increase Antibody Yield During Ion Exchange Chromatography
29 Dec 22
The present invention relates to a method for increasing antibody yield during antibody purification from a sample by ion exchange chromatography in flow-through mode by pre-conditioning the sample with Tris without the use of NaCl to adjust the conductivity.
Daniela DAUBERT, Dominik GELTINGER, Karin FELDERER
Filed: 20 Nov 20
Utility
Humanized antibodies for CD3
18 Oct 22
The present disclosure provides humanized antibodies that specifically bind to CD3 with an optimized affinity and induce T cell-mediated killing of tumour related target antigen high expressing cells with high potency but have limited killing activity on target antigen low expressing cells.
Thomas Tiller, Steffen Runz, Julia Neugebauer, Andreas Bültmann
Filed: 13 Aug 18
Utility
Methods for Predicting Therapeutic Benefit of ANTI-CD19 Therapy In Patients
8 Sep 22
The present disclosure is directed to identifying characteristics and biomarkers in patients that benefit from treatment with an anti-CD19 antibody.
Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
Filed: 25 May 22
Utility
ANTI-CD19 Therapy In Patients Having a Limited Number of NK Cells
4 Aug 22
The present disclosure provides characteristics and biomarkers in patients that benefit from treatment with anti-CD19 antibodies (MOR00208, XmAb5574).
Christian KUFFER, Guenter FINGERLE-ROWSON, Mark WINDERLICH, Jan ENDELL
Filed: 4 May 20
Utility
ANTI-CD19 Combination Therapy
16 Jun 22
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma.
Günter FINGERLE-ROWSON, Wolfram BRUGGER, Oliver MANZKE, Francis SEGUY
Filed: 3 Dec 21
Utility
Anti-CD19 antibody formulations
7 Jun 22
The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.
Patrick Garidel, Andreas Langer, Martin Hessling, Daniel Weinfurtner, Bodo Brocks
Filed: 27 Jun 17
Utility
Peptide libraries
7 Jun 22
The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses.
Katja Siegers, Jan Van Den Brulle
Filed: 8 Sep 20
Utility
ANTI-CD38 Antibodies and Pharmaceutical Compositions Thereof for the Treatment of Autoantibody-mediated Autoimmune Disease
12 May 22
The present invention relates to the use of an antibody or antibody fragment specific for CD38 in the prophylaxis and/or treatment of autoantibody-mediated autoimmune disease.
Daniel KLUNKER, Rainer BOXHAMMER, Stefan HÄRTLE, Stefan STEIDL, Tiantom JARUTAT
Filed: 13 Mar 20
Utility
Antibodies Targeting C5AR
5 May 22
The present invention provides novel antibodies or antibody fragments specifically binding to human C5aR.
Julia NEUGEBAUER, Barbara BACHLER-KONETZKI, Tanja HERRMANN, Winfried ELLIS
Filed: 13 Mar 20
Utility
FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 Region
5 May 22
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region.
Julia NEUGEBAUER, Steffen RUNZ, Stefanie URLINGER
Filed: 10 Jan 22
Utility
Antibody Formulations
14 Apr 22
The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody.
Bodo BROCKS, Robert KELLERER
Filed: 13 Dec 19
Utility
Combinations and Uses Thereof
24 Mar 22
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jan ENDELL, Mark WINDERLICH, Rainer BOXHAMMER
Filed: 8 Dec 21
Utility
Fab molecules with a rodent hinge region and a non-rodent CH1 region
22 Feb 22
The disclosure relates to novel Fab molecules comprising a modified heavy chain constant region.
Julia Neugebauer, Steffen Runz, Stefanie Urlinger
Filed: 13 Nov 17
Utility
Pharmaceutical Combinations for Treating Tumor Comprising ANTI-CD19 Antibody and Natural Killer Cell
17 Feb 22
Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same.
Jung Hyun HER, Mi Young JUNG, Su Hyun GWON, Ho Yong LIM, Sung Yoo CHO, Sung Yong WON, Yu Kyeong HWANG, Jan ENDELL, Rainer BOXHAMMER
Filed: 5 Sep 19
Utility
Multispecific Antigen-binding Molecules
10 Feb 22
Novel antigen-binding molecules are provided, with the ability to target different antigens with different valency, e.g. one antigen monovalently and another antigen bivalently.
Andreas Bültmann, Karin Felderer, Sebastian Jäger, Steffen Runz, Johannes Urban
Filed: 4 Dec 19
Utility
Combinations and uses thereof
18 Jan 22
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Jan Endell, Mark Winderlich, Rainer Boxhammer
Filed: 18 Aug 16
Utility
Anti-gm-csf Antibodies
11 Nov 21
The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions.
Stefan STEIDL, Elisabeth THOMASSEN-WOLF
Filed: 7 May 21